Navigation Links
Bayer and Onyx Announce Nexavar Data Presentations at 60th American Association for the Study of Liver Diseases Annual Meeting
Date:10/29/2009

Gastroenterologie, Hepatologie und Infektiologie, Heinrich-Heine-Universitat Dusseldorf, Dusseldorf, Germany
  • Tuesday, November 3, 2009, 8:00 a.m. - 1:00 p.m., Exhibit Hall C
  • Abstract #1675
  • Efficacy and Safety of Sorafenib in Patients from the Asia-Pacific (AP) Region with Advanced Hepatocellular Carcinoma (HCC): Impact of Prior Transarterial Chemoembolization and Transarterial Embolization (TACE/TAE)

    • Dr. Zhendong Chen, First Affiliated Hospital of Anhui Medical University, Hefei, China
    • Tuesday, November 3, 2009, 8:00 a.m. - 1:00 p.m., Exhibit Hall C
    • Abstract #1694

    "Liver cancer is often diagnosed at an advanced stage when patients tend to be very ill due to pre-existing liver disease," said Todd Yancey, M.D., vice president of clinical development at Onyx. "Onyx and Bayer are committed to evaluating Nexavar in ongoing studies, as will be presented at AASLD, in order to realize the potential benefit the therapy may offer to patients at all stages of the disease and in different treatment settings."

    Nexavar's Differentiated Mechanism

    Nexavar targets both the tumor cell and tumor vasculature. In preclinical studies, Nexavar has been shown to target members of two classes of kinases known to be involved in both cell proliferation (growth) and angiogenesis (blood supply) - two important processes that enable cancer growth. These kinases included Raf kinase, VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-B, KIT, c-FLT-3 and RET.

    Nexavar is currently approved in more than 80 countries for the treatment of patients with liver cancer and in more than 90 countries for the treatment of patients with advanced kidney cancer. Nexavar is also being evaluated by the companies, international study groups, government agencies and individual investigators as a single agent or combination treatment in a wide range of cancers, including breast cancer,
    '/>"/>

    SOURCE Onyx Pharmaceuticals, Inc.; Bayer HealthCare Pharmaceuticals Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related medicine technology :

    1. Bayers Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients
    2. Bayer Announces New Data on Oncology Portfolio To Be Presented at the ECCO-ESMO Congress 2009
    3. Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
    4. Bayer Announces New Data on Novel Anti-cancer Compound BAY 73-4506
    5. Bayer Announces Leukine(R) Data Presentations at 45th American Society of Clinical Oncology (ASCO) Annual Meeting
    6. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
    7. Bayer Announces Upcoming Presentations of Campath(R) and Leukine(R) Data at the 50th Annual Meeting of the American Society of Hematology
    8. FDA Approves Bayer HealthCares Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A
    9. Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer
    10. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
    11. Bayer HealthCare Celebrates 20th Anniversary of Kogenate(R) Product Line and 8 Billion IU Milestone at 2008 WFH World Congress
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/23/2014)... MINNEAPOLIS , July 23, 2014 ... they have added 14 new vendors so far ... Creekridge,s newest vendors are from both ... mid-size domestic organizations to large, well-known multi-national companies. ... Creekridge,s diversified suite of financing products including: standard ...
    (Date:7/23/2014)... South Korea , July 23, 2014  Mezzion ... clinical program to evaluate the use of udenafil to ... for single ventricle heart defects. The clinical program will ... representatives of the Pediatric Heart Network (PHN), a multi-center ... and Blood Institute (NHLBI) of the National Institutes of ...
    (Date:7/23/2014)... LONDON , July 23, 2014  Lightlake ... developing addiction treatments based on its expertise in ... an investigational new drug application ("IND") with respect ... Lightlake also announced today that it has received ... Drug Abuse ("NIDA"), part of the National Institutes ...
    Breaking Medicine Technology:Creekridge Capital Signs Several New Vendor Partners 2Mezzion Pharma Initiates Clinical Development Program To Evaluate Udenafil In Adolescents With Single Ventricle Heart Defects 2Lightlake Therapeutics Inc. Files Investigational New Drug Application For Naloxone Nasal Spray For Reversing Opioid Overdose And Announces A Further Collaboration With The National Institute On Drug Abuse 2Lightlake Therapeutics Inc. Files Investigational New Drug Application For Naloxone Nasal Spray For Reversing Opioid Overdose And Announces A Further Collaboration With The National Institute On Drug Abuse 3
    (Date:7/23/2014)... 2014 In its latest blog post, ... that having family close by during a stay in rehab ... process is successful, is focusing on a topic that is ... addiction-related dialogues: opiate abuse facts. , The Best Drug Rehabilitation ... An overview of opiates, and why they’re considered “the ...
    (Date:7/23/2014)... (PRWEB) July 23, 2014 The Europe Drilling ... drilling fluid and completion fluid market in Europe with analysis ... market in Europe is estimated to grow from around $1.3 ... CAGR of 6.1%, for the given period. , Browse through ... Market Report, to get an idea of the in-depth analysis ...
    (Date:7/23/2014)... 2014 AidJoy is delighted to announce that ... Zen on September 5, 2014 from 7:00 to 11:00 ... are expected to attend this semi-formal event. , "We are ... past six years," says Jess Dennis, Director of Operations and ... on this moment in AidJoy’s history before we launch into ...
    (Date:7/23/2014)... 2014 "I wanted a better way to ... my blood sugar, blood pressure and pulse rate," said an ... have to carry along a bunch of different devices, so ... developed the Master III to make it easier to monitor ... convenient unit. The accessory enables the user to have more ...
    (Date:7/23/2014)... shown that some high-profile athletes who suffered repeated blows ... clumps in their brains. Those clumps suggest the athletes ... scientists are working on tests that might be able ... an article in Chemical & Engineering News (C&EN) ... Society. , In the article, Lauren Wolf, a senior ...
    Breaking Medicine News(10 mins):Health News:Latest Best Drug Rehabilitation Blog Post Focuses on Opiate Abuse Facts 2Health News:Europe Drilling Fluid & Completion Fluid Market is Expected to Reach $1.7 Billion in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Drilling Fluid & Completion Fluid Market is Expected to Reach $1.7 Billion in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Drilling Fluid & Completion Fluid Market is Expected to Reach $1.7 Billion in 2018 - New Report by MicroMarket Monitor 4Health News:Europe Drilling Fluid & Completion Fluid Market is Expected to Reach $1.7 Billion in 2018 - New Report by MicroMarket Monitor 5Health News:Europe Drilling Fluid & Completion Fluid Market is Expected to Reach $1.7 Billion in 2018 - New Report by MicroMarket Monitor 6Health News:AidJoy’s Inaugural Gala to be Held September 5, 2014 2
    ... who regularly complain of fatigue can increase their energy levels ... by engaging in regular, low intensity exercise, according to a ... that a quick workout will leave us worn out ... Puetz, who recently completed his doctorate at UGA and is ...
    ... Launch New Accreditation Program This Spring, LOVELAND, ... (PHII), a non-profit 501(c)(3) organization that promotes,credible, transparent, ... announces the election of Joel V.,Brill, MD; Garry ... to the PHII,Board of Directors. They will join ...
    ... Philadelphia, PA, February 28, 2008 There is a ... adults diagnosed with schizophrenia. However, there is a ... and adolescents with schizophrenia. Although the U.S. Food ... of aripiprazole and risperidone for adolescents with schizophrenia, few ...
    ... of dermatologist endorsed moisturizers, MEMPHIS, Tenn., Feb. ... full line of dermatologist endorsed moisturizers especially,created to ... launching its 2008,"Prepare to Unveil Yourself" initiative with ... skin. Four Theraplex(R) solutions:,HydroLotion, ClearLotion, Emollient, and Theraplex ...
    ... (NEWARK, N.J., Feb. 28, 2008) New Jersey State ... Administration Research Education) Award for Excellence in Research to ... Flynn, assistant professor at the College of Nursing at ... honored with three other C.A.R.E. award recipients during the ...
    ... Feb. 28 Boston Scientific,Corporation (NYSE: ... implants of its,COGNIS(TM) cardiac resynchronization therapy defibrillator ... began,performing implants earlier this week. Forty implants ... countries., When choosing a high-energy device, ...
    Cached Medicine News:Health News:Low-intensity exercise reduces fatigue symptoms by 65 percent, study finds 2Health News:Population Health Impact Institute Announces New Board Members 2Health News:Comparison of antipsychotic treatments in adolescents with schizophrenia 2Health News:Prepare to Unveil Yourself with Theraplex(R) for Spring and Summer 2008 2Health News:Prepare to Unveil Yourself with Theraplex(R) for Spring and Summer 2008 3Health News:Prepare to Unveil Yourself with Theraplex(R) for Spring and Summer 2008 4Health News:Boston Scientific Announces First European Implants of New Devices to Treat Heart Failure and Sudden Cardiac Death 2Health News:Boston Scientific Announces First European Implants of New Devices to Treat Heart Failure and Sudden Cardiac Death 3Health News:Boston Scientific Announces First European Implants of New Devices to Treat Heart Failure and Sudden Cardiac Death 4
    Surgical Stainless Steel Adult 16.5....
    Ultra-Slip™ endotracheal tube guide for single-patient use only., ,Caution: Not MRI Compatible....
    FlexiSlip™ Plastic coated malleable metal core. Single use, Sterile, Latex Free. Soft distal tip flexes to reduce risk of trauma to patient. Malleable metal core is easy to shape. Low friction ...
    FlexiSlip™ Plastic coated malleable metal core. Single use, Sterile, Latex Free. Soft distal tip flexes to reduce risk of trauma to patient. Malleable metal core is easy to shape. Low friction ...
    Medicine Products: